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SUMMARY
The Cdc25A phosphatase positively regulates cell-cycle transitions, is degraded by the proteosome through-
out interphase and in response to stress, and is overproduced in human cancers. The kinases targeting
Cdc25A for proteolysis during early cell-cycle phases have not been identified, and mechanistic insight
into the cause of Cdc25A overproduction in human cancers is lacking. Here, we demonstrate that glycogen
synthase kinase-3b (GSK-3b) phosphorylates Cdc25A to promote its proteolysis in early cell-cycle phases.
Phosphorylation byGSK-3b requires priming of Cdc25A, and this can be catalyzed by polo-like kinase 3 (Plk-3).
Importantly, a strong correlation between Cdc25A overproduction and GSK-3b inactivation was observed
in human tumor tissues, indicating that GSK-3b inactivation may account for Cdc25A overproduction in
a subset of human tumors.INTRODUCTION
Cancer cells frequently overproduce proteins that positively reg-
ulate the cell division cycle in order to maintain their proliferative
capacity. The Cdc25A protein phosphatase is an example of
a key cell-cycle regulator that isoverproduced in manyhuman can-
cers (Kristjansdottir and Rudolph, 2004). Cdc25A drives the cell
cycle forward by activating cyclin-dependent protein kinases
(Cdks). Cells regulate the activity and abundance of Cdc25A
through transcriptional activation, reversible phosphorylation,
protein-protein interactions, and ubiquitin-mediated proteolysis
(Bernardi et al., 2000; Boutros et al., 2006; Busino et al., 2004;
Chen et al., 2003). In addition to tightly controlling Cdc25A during
a normal cell cycle, cells rapidly shunt Cdc25A for ubiquitin-
mediated proteolysis when they are exposed to genotoxic stress36 Cancer Cell 13, 36–47, January 2008 ª2008 Elsevier Inc.(Mailand et al., 2000; Molinari et al., 2000). By eliminating
Cdc25A, cells are able to temporarily arrest the cell division cycle
to allow time for DNA repair.
Cdc25A ubiquitination is mediated by two distinct E3 ubiquitin
ligases (Busino et al., 2003, 2004; Donzelli et al., 2002; Jin et al.,
2003; Ray et al., 2005). APC/CCdh1 targets Cdc25A for destruc-
tion during mitotic exit and early G1, whereas SCFbTrCP targets
Cdc25A during G1, S, and G2. The importance of Cdc25A regu-
lation is underscored by the observation that its overproduction
leads to accelerated entry of cells into both S phase (Blomberg
and Hoffmann, 1999) and mitosis (Molinari et al., 2000) and fail-
ure to regulate Cdc25A during a checkpoint response causes
bypass of DNA damage and replication checkpoints, resulting
in enhanced DNA damage (Bartek and Lukas, 2001; Falck
et al., 2001; Mailand et al., 2000; Molinari et al., 2000; ZhaoSIGNIFICANCE
Our study identifies two Cdc25A regulators and provides a molecular mechanism to account for Cdc25A overproduction in
human cancers. A therapeutic strategy being developed to treat p53-deficient cancers combines DNA-damaging agents
with drugs, such as UCN-01, to induce Cdc25A accumulation. This results in preferential killing of p53-deficient tumors be-
cause all DNA damage checkpoints are eliminated in these tumors. Our study identifies GSK-3b and Plk-3 as potential ther-
apeutic targets whose inhibition may induce checkpoint bypass in tumors by blocking Cdc25A proteolysis. Furthermore,
tumors from patients enrolled on clinical trials that depend on Cdc25A stabilization to induce checkpoint bypass should
be tested for the integrity of the GSK-3b/Plk-3/Cdc25A pathway in order to correlate Cdc25A levels with tumor responses.
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mammals is intimately linked to the Cdc25A-regulatory pathway.
Phosphorylation serves to both promote and protect Cdc25A
from ubiquitin-mediated proteolysis. Phosphorylation of Cdc25A
on S76 is required for its ubiquitin-mediated proteolysis (Donzelli
et al., 2004; Goloudina et al., 2003). In addition, phosphorylation
of serines 82 and 88 regulates Cdc25A destruction by facilitating
recognition of Cdc25A by SCFbTrCP (Busino et al., 2003; Jin et al.,
2003). In contrast, phosphorylation of Cdc25A on serines 18 and
116 prevents proteasome-mediated degradation of Cdc25A
during mitosis (Mailand et al., 2002).
Cdc25A is regulated by several protein kinases. Cdk2 acti-
vates Cdc25A during the G1/S transition (Hoffmann et al.,
1994). Cdk1 phosphorylates Cdc25A during mitosis on serine
18 and 116 to uncouple it from ubiquitin-mediated proteolysis
(Mailand et al., 2002). In turn, Cdc25A accumulation enhances
Cdk1 activation. The Chk1 protein kinase phosphorylates
Cdc25A in S and G2 under normal conditions and in response
to checkpoint activation (Zhao et al., 2002). Chk1 phosphory-
lates Cdc25A on S76 to target it for ubiquitin-mediated proteol-
ysis and on T507 to prevent Cdc25A from activating Cdk1 in
S and G2 (Chen et al., 2003; Donzelli et al., 2004; Falck et al.,
2001; Goloudina et al., 2003; Hassepass et al., 2003; Sorensen
et al., 2003; Zhao et al., 2002). Cdc25A is also targeted for ubiq-
uitin-mediated proteolysis during G1 but the kinase(s) that regu-
late its ubiquitination in G1 has not been identified.
GSK-3b is a serine/threonine protein kinase that operates in
G1 to receive input from several signaling and developmental
pathways (Cohen and Frame, 2001; Doble and Woodgett,
2003). GSK-3b phosphorylates cyclin D1 and c-Myc to promote
their destruction in G1. Thus, signaling pathways that inactivate
GSK-3b, such as the PI-3K/AKT and MAPK pathways, promote
cell-cycle entry by stabilizing proteins such as cyclin D1 and
c-Myc (Diehl et al., 1998; Doble and Woodgett, 2003). Here, we
demonstrate that GSK-3b regulates the ubiquitin-mediated
proteolysis of Cdc25A during early phases of the cell cycle and
overproduction of Cdc25A strongly correlates with GSK-3b
inactivation in human tumors.
RESULTS
Identification of GSK-3b as a Potential Regulator of
Cdc25A
Transcriptional activation of Cdc25A begins in G1, and Cdc25A
protein levels begin to rise as cells advance toward S phase.
However, Cdc25A accumulation is counterbalanced by its ubiq-
uitin-mediated proteolysis, which occurs throughout the G1, S,
and G2 phases of the cell division cycle (Busino et al., 2004).
The Chk1 protein kinase is active during the S and G2 phases
of the cell cycle and contributes to the ubiquitin-mediated prote-
olysis of Cdc25A during these two phases (Busino et al., 2004;
Busino et al., 2003; Jazayeri et al., 2006). However, the protein
kinases that regulate the turnover of Cdc25A during mid- to
late-G1 have not been identified. In searching for protein kinases
that might fulfill this role, we identified kinases that are active in
the G1 phase of the cell cycle, and we examined Cdc25A to de-
termine if it contained consensus phosphorylation sites for the
G1-active kinase(s). GSK-3b met both criteria. GSK-3b activity
is highest in quiescent and G1 phase cells and decreases as cellsprogress through the cell cycle (Cohen and Frame, 2001; Doble
and Woodgett, 2003). An examination of the amino acid se-
quence of Cdc25A revealed that S76, a key regulatory site that
is required for the ubiquitin-mediated proteolysis of Cdc25A,
conforms to a minimal GSK-3b consensus motif.
The classic GSK-3b consensus motif is (S/T)XXX(S/T)* where X
is any amino acid and potential GSK-3b phosphorylation sites
are underlined (Cohen and Frame, 2001; Doble and Woodgett,
2003). GSK-3b often requires that its substrates first be phos-
phorylated at a serine or threonine residue in the +4 position rel-
ative to the GSK-3b phosphorylation site. This residue is referred
to as the priming site (indicated by an asterisk). Of the residues
known to be required for the ubiquitin-mediated proteolysis of
Cdc25A (S76, S82, and S88), only sequences surrounding and
inclusive of S76 conform to a GSK-3b motif (S76SEST80*).
Several experiments were performed to determine if GSK-3b
negatively regulates Cdc25A in vivo. First, HeLa and U2OS cells
were treated with LiCl, a potent GSK-3b inhibitor (Yin et al.,
2006). As seen in Figure 1A, endogenous Cdc25A accumulated
in cells treated with either LiCl (lanes 2 and 6) or MG132 (lanes 3
and 7), an inhibitor of the 26S proteasome. An even greater sta-
bilization of endogenous Cdc25A was observed when cells were
treated with both LiCl and MG132 (lanes 4, and 8). Note that en-
dogenous b-catenin, a downsteam effector of GSK-3b, was also
Figure 1. Cdc25A Protein Levels Are Negatively Regulated by GSK-
3b In Vivo
(A) Asynchronously growing HeLa and U2OS cells were untreated or were
incubated with 10 mM LiCl, 10 mM MG132, or both for 4 hr (n = 3). The indicated
proteins were analyzed by western blotting.
(B) H460 cells transfected with plasmids encoding the indicated proteins for
20 hr were untreated or were incubated with 10 mM MG132 for 4 hr (n = 2)
and analyzed by western blotting.
(C) HeLa cells transfected with scrambled siRNA for 44 hr were cultured in the
absence or presence of 10 mM LiCl for 4 hr (n = 3). Alternatively, cells were
transfected with siRNAs specific for GSK-3b or Chk1 for 48 hr and the indi-
cated proteins were analyzed by western blotting.Cancer Cell 13, 36–47, January 2008 ª2008 Elsevier Inc. 37
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Cdc25A also accumulated in cells treated with other GSK-3b
specific inhibitors, including 1-Azakenpaullone, SB216763, and
SB415286 (data not shown) (Coghlan et al., 2000; Kunick et al.,
2004). Accumulation of Cdc25A was also observed in normal
human diploid fibroblasts (IMR90) and several cancer cell lines,
including MDA-MB-231, H460, A549, MCF-7, Saos2, and
BT549 (Figure S1A and data not shown). Ectopically-produced
Cdc25A was also observed to accumulate in cells treated with
LiCl, MG132, or both (Figure S1B). Next, endogenous Cdc25A
levels were monitored in cells overproducing constitutively-
active (CA) or kinase-inactive (KD) GSK-3b. As seen in Figure 1B,
Cdc25A protein levels were reduced in cells expressing GSK-
3b-CA (lane 3) relative to cells expressing either vector (lane 1)
or kinase-inactive GSK-3b (lane 2), and Cdc25A levels were re-
stored in cells treated with MG132 (lane 4). Experiments were
also carried out using GSK-3b- and Chk1-specific siRNAs, with
Chk1-siRNAs serving as a positive control (Zhao et al., 2002).
As seen in Figure 1C, knockdown of GSK-3b (lane 3) stabilized
endogenous Cdc25A, as did knockdown of Chk1 (lane 4).
Knockdown of GSK-3b did not affect levels of GSK-3a (lane 3)
demonstrating that stabilization of Cdc25A was due to loss of
Figure 2. GSK-3b Promotes Cdc25A Turnover dur-
inganUnperturbedCellCycleand inResponse to IR
(A) Asynchronously growing HeLa cells were treated with
PBS or 10 mM LiCl for 4 hr, and then 10 mg/ml cyclohexi-
mide (CHX) was added for the indicated times (n = 3). Pro-
teins were analyzed by western blotting.
(B) HeLa cells transfected with either GSK-3b siRNA or
scrambled siRNA for 48 hr were incubated in the presence
of 10 mg/ml CHX for the indicated times (n = 3). Proteins
were analyzed by western blotting.
(C) HeLa cells were transfected with GSK-3b or scrambled
siRNAs for 48 hr (n = 2), and cells were then mock-irradi-
ated or were treated with 10 Gy IR and harvested at times
indicated. Proteins were analyzed by western blotting.
(D) HeLa cells were untreated or were incubated with
10 mM LiCl, 100 nM Go¨6976, or both for 4 hr. Cells were
then mock-irradiated or were treated with 10 Gy IR and
harvested at times indicated (n = 2). Proteins were ana-
lyzed by western blotting. Relative levels of Cdc25A
were determined from western blots using the ImageJ
program and are indicated above the respective blots.
GSK-3b rather than to loss of both GSK-3b
and GSK-3a. Cdc25A levels rise as cells ad-
vance through the cell division cycle (Busino
et al., 2004). FACs analysis was performed to
ensure that GSK-3b knockdown did not cause
a significant fraction of the cells to move into
and remain in late cell-cycle phases. If this
were the case, the observed stabilization of
Cdc25A could be due to an indirect effect
of cell-cycle position rather than a direct effect
of GSK-3b loss. Under the time course of the
experiment (48 hr), knockdown of GSK-3b
and Chk1 did not significantly alter cell-cycle
profiles (Figures S2A–S2D), demonstrating that
Cdc25A stabilization was not an indirect ef-
fect of cell-cycle alterations. However, GSK-
3b inactivation in synchronized populations of G1 cells led
to an accelerated S phase entry (Figure 6 and Figure S5).
Taken together, these results suggest that GSK-3b negatively
regulates Cdc25A abundance in vivo. Myc, a downstream
target of GSK-3b, has been reported to positively regulate
the ubiquitin-mediated proteolysis of Cdc25A (Bernardi
et al., 2000). However, GSK-3b inhibition did not change
Myc levels under our experimental conditions, ruling out the
possibility that the stabilization of Cdc25A observed upon
GSK-3b inhibition is mediated by increased levels of Myc
(Figure S2E).
GSK-3b Promotes the Turnover of Cdc25A during an
Unperturbed Cell Cycle and in Response to Ionizing
Radiation
If GSK-3b promotes the turnover of Cdc25A in vivo, then treat-
ment of cells with GSK-3b-specific inhibitors is expected to pro-
long the half-life of Cdc25A.
As seen in Figure 2, both Cdc25A and b-catenin were stabi-
lized in cells treated with either LiCl (Figure 2A) or GSK-3b-spe-
cific siRNAs (Figure 2B). Moreover, GSK-3b inhibition also
prolonged the half-life of Cdc25A in cells exposed to ionizing38 Cancer Cell 13, 36–47, January 2008 ª2008 Elsevier Inc.
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the turnover of Cdc25A both during an unperturbed cell cycle
and in response to genotoxic stress. The half-life of Cdc25A
was less than 30 min in cells with intact GSK-3b (Figure 2A, lanes
4–6 and Figure 2B, lanes 4–6). In contrast, the half-life of Cdc25A
was prolonged in cells where GSK-3b was inhibited pharmaco-
logically (Figure 2A, lanes 1–3) or by knockdown with siRNAs
(Figure 2B, lanes 1–3). This was also true in irradiated cells (Fig-
ures 2C and 2D). The contributions made by Chk1 and GSK-3b
to Cdc25A degradation was also monitored in cells where each
kinase was inhibited singly or simultaneously. LiCl was used to in-
hibit GSK-3b (lanes5–8), and Go¨6976 (Kohn et al., 2003) was used
to inhibit Chk1 (lanes 13–16). As seen in Figure 2D (lanes 9–12),
GSK-3b and Chk1 cooperate in regulating Cdc25A proteolysis
in vivo both in the presence and absence of genotoxic stress.
GSK-3b Interacts with Cdc25A
We next asked if complexes between endogenous Cdc25A and
GSK-3b could be detected in vivo. As seen in Figure 3A, GSK-3b
was present in Cdc25A immunoprecipitates (lane 3), but not in
normal rabbit IgG precipitates (lane 2). In addition, interactions
between ectopically produced Cdc25A and GSK-3b could also
be detected in vivo (Figure 3B). These results demonstrate that
Cdc25A and GSK-3b stably associate in vivo. In many cases
the association between GSK-3b and its substrates requires
that the substrate first be phosphorylated on a priming site
(Cohen and Frame, 2001; Doble and Woodgett, 2003). Mutation
of R96 to alanine has been shown to disrupt interactions be-
tween GSK-3b and those substrates that require priming. Flag-
Cdc25A was coproduced with wild-type and mutant forms of
GSK-3b. As seen in Figure 3C, Cdc25A levels were lower in cells
overproducing wild-type GSK-3b (lane 3) relative to control cells
(lane 5) but higher in cells overproducing kinase-inactive GSK-3b
(lane 2) or the R96A mutant (lane 4). These results suggest that
Cdc25A may be a substrate of GSK-3b and that GSK-3b prefers
that Cdc25A first be phosphorylated on a priming site.
Regulation of Cdc25A by GSK-3b and Plk-3
In Vivo and In Vitro
Sequences surrounding and inclusive of S76 (S76XXXT80*) con-
form to the minimal motif (S/TxxxS/T*) for the priming-required
substrates of GSK-3b (Cohen and Frame, 2001; Doble and
Woodgett, 2003). Interestingly, phosphorylation of Cdc25A on
S76, but not S123, was reduced in cells treated with LiCl
(Figure 4A, lane 3) and coproduction of Cdc25A with constitu-
tively active GSK-3b enhanced S76 phosphorylation (Figure 4B,
lane 2). These data are consistent with the hypothesis that
GSK-3b regulates S76 phosphorylation. Next, experiments
were performed to determine if T80 served a priming function
to enable phosphorylation of S76. An antibody that specifically
recognizes Cdc25A when it is phosphorylated on T80 demon-
strated that Cdc25A is phosphorylated on T80 in vivo (Figure 4C),
and substitution of alanine for threonine at position 80 (T80A)
severely curtailed phosphorylation of Cdc25A on S76 in vivo
(Figure 4D, lane 3). In addition, although S76 phosphorylation
was enhanced when Cdc25A was coexpressed with constitu-
tively active GSK-3b in murine embryonic fibroblasts (MEFs)
null for GSK-3b (Figure 4E, lane 2), enhanced phosphorylation
of Cdc25A on S76 was not observed when the T80A mutant ofCdc25A was coexpressed with constitutively active GSK-3b in
null MEFs (Figure 4E, lane 4). As expected, T80A bound less
GSK-3b (Figure 4E, lane 4) than did WT Cdc25A (lane 2). The
S76A and T80A mutants were relatively insensitive to coexpres-
sion with GSK-3b (Figure S3A) and to LiCl-treatment (Figure S3B).
We conclude that S76 phosphorylation by GSK-3b is dependent
upon prior phosphorylation of Cdc25A on T80. It is worth noting
that S76 phosphorylation was still detected, albeit at a much
lower level, when either wild-type Cdc25A (Figure 4E, lane 1) or
the T80A mutant (Figure 4E, lane 3) were expressed in GSK-3b
null MEFs. Importantly, S76 phosphorylation was observed to
decrease when GSK-3b null MEFs were treated with the Chk1 in-
hibitor, Go¨6976 (Kohn et al., 2003), suggesting that Chk1 contrib-
utes to S76 phosphorylation in cells null for GSK-3b (Figure S4A).
Figure 3. Interactions between Cdc25A and GSK-3b
(A) MDA-MB-231 cells incubated with 10 mM MG132 for 4 hr were lysed and
either analyzed directly by western blotting (lane 1) or were first incubated
with rabbit anti-Cdc25A antibody (lane 3) or normal rabbit IgG (lane 2). Immu-
noprecipitates (IP) were analyzed by western blotting (lanes 2 and 3), n = 2.
WCL, whole cell lysate.
(B) Lysates were prepared from HeLa cells transfected with the indicated pro-
teins for 24 hr. WCL were resolved directly by SDS-PAGE (lanes 1–4) or were
first incubated with antibodies specific for either the Flag epitope (lanes 5–8)
or the V5 epitope (lane 9–12). Precipitates were analyzed by western blotting.
Asterisks denote V5-GSK-3b and Flag-Cdc25A in the coprecipitates, n = 2.
(C) HeLa cells were cotransfected with the indicated plasmids for 24 hr (n = 2),
and proteins were analyzed by western blotting. Relative levels of Flag-
Cdc25A are indicated.Cancer Cell 13, 36–47, January 2008 ª2008 Elsevier Inc. 39
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GSK-3b directly phosphorylates Cdc25A on S76. Cdc25A was
purified as a GST fusion protein from bacteria, and S76 phos-
phorylation was monitored with a phosphospecific antibody
that recognizes Cdc25A when it is phosphorylated on S76. As
seen in Figure 4F, incubation of GST-Cdc25A with purified
GSK-3b did not increase the reactivity of Cdc25A with the
pS76-specific antibody above background (compare lanes 1
and 2). Given that the recombinant Cdc25A used in the assay
was purified from bacteria, it was unlikely to be phosphorylated
on T80, the priming site. Therefore, we searched for kinases that
would phosphorylate Cdc25A on T80 in vitro. Sequences sur-
rounding and inclusive of T80 (ExT80) conform to a Polo-like ki-
nase (Plk) phosphorylation site (D/ExS/T). The Plk family consists
of four family members Plk-1 to -4. Plk-2 and -3 are active in the
G1 phase of the cell cycle when GSK-3b is expected to regulate
Cdc25A, whereas Plk-1 and -4 function in late G2 and mitosis
(Eckerdt et al., 2005; Winkles and Alberts, 2005; Zimmerman
and Erikson, 2007). Plk-3 was tested for its ability to prime
Cdc25A for subsequent phosphorylation by GSK-3b. As seen
in Figure 4F, incubation of GST-Cdc25A with purified Plk-3 did
not increase the reactivity of Cdc25A with the pS76-specific
Figure 4. Regulation of Cdc25A by GSK-3b and
Plk-3
(A) U2OS cells transfected with Flag-tagged wild-type
Cdc25A (WT) or S76A for 20 hr were cultured in the ab-
sence or presence of 10 mM LiCl for 4 hr. Tagged proteins
were precipitated and analyzed by western blotting using
anti-p-S76-Cdc25A antibody (top panel), anti-p-S123-
Cdc25A antibody (middle panel), or anti-Cdc25A antibody
(bottom panel), n = 2.
(B) U2OS cells transfected with the indicated plasmids for
24 hr were lysed and Cdc25A was precipitated with anti-
bodies specific to the Flag tag. Precipitates were analyzed
by western blotting, n = 2.
(C) HEK293 cells were transfected with the indicated plas-
mids for 24 hr followed by western blotting, n = 2.
(D) U2OS cells were transfected with the indicated plas-
mids for 24 hr and analyzed as described in (A), n = 2.
(E) Immortalized GSK-3b null MEFs were transfected with
plasmids encoding Flag-Cdc25A together with either
empty vector or vector encoding HA-tagged constitutively
active (CA) GSK-3b for 20 hr. Cells were treated with
MG132 for 4 hr, lysed and analyzed directly by western
blotting (bottom 3 panels), or were incubated with Flag
agarose prior to western blotting (top 3 panels), n = 2.
(F) Recombinant GST-Cdc25A was purified from bacteria
and kinase reactions were performed in vitro in the ab-
sence or presence of purified Plk-3, GSK-3b, or both, as
described in the Experimental Procedures. Reaction prod-
ucts were analyzed by western blotting with the indicated
antibodies, n = 4.
(G) HEK293 cells were cotransfected with plasmids en-
coding the indicated proteins for 24 hr followed by western
blotting, n = 2.
antibody above background (top panel, lanes 1
and 4). However, prior phosphorylation of
Cdc25A by Plk-3 significantly enhanced the
ability of GSK-3b to phosphorylate Cdc25A on
S76 in vitro (top panel, lane 3). Importantly,
Plk-3 directly phosphorylated Cdc25A on T80 in vitro (middle
panel, lanes 3 and 4), and incubation of the T80A mutant with
Plk-3 did not facilitate S76 phosphorylation by GSK-3b (lane 7).
The altered electrophoretic mobility of wild-type Cdc25A and
the T80A mutant indicated that sites other than T80 were also
phosphorylated by Plk-3 in vitro.
To further investigate the contribution made by Plk family
members to Cdc25A regulation in vivo, Cdc25A was coproduced
with Plk-3 in vivo. As seen in Figure 4G, this resulted in enhanced
phosphorylation of Cdc25A on T80, and siRNA knockdown of
Plk-3, but not other family members, resulted in Cdc25A stabili-
zation in vivo (data not shown). These results are consistent with
Plk-3 serving a priming function for Cdc25A in vivo.
Regulation of Cdc25A Stability by S76 and T80
Phosphorylation
Given that S76 phosphorylation by GSK-3b is dependent on T80
phosphorylation and that the ubiquitin-mediated proteolysis of
Cdc25A is dependent on S76 phosphorylation, it is predicted
that mutants of Cdc25A that cannot be phosphorylated on T80
would have a longer half-life than wild-type Cdc25A. This was in-
deed the case as shown in Figures 5A and 5B. The half-life of the40 Cancer Cell 13, 36–47, January 2008 ª2008 Elsevier Inc.
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Promotes b-TrCP Binding and Ubiquitin-Mediated
Proteolysis
(A and B) U2OS cells transfected with Flag-tagged ver-
sions of Cdc25A for 16 hr were incubated with 10 mg/ml
CHX for the indicated times (n = 3). Cdc25A protein levels
were quantified from western blots using chemilumines-
cence on a STORM imager (A) and the data are illustrated
graphically (B).
(C) U2OS were cotransfected with plasmids encoding
Myc-b-TrCP and the indicated forms of Flag-Cdc25A for
24 hr. Lysates were analyzed directly by western blotting
(bottom three panels) or lysates were first incubated with
Flag agarose, and Cdc25A precipitates were analyzed
by western blotting (top two panels). The relative ratio of
b-TrCP to Cdc25A was determined from three indepen-
dent experiments using chemiluminescence on a STORM
imager or the ImageJ program. A representative western
blot is shown. The binding of b-TrCP to WT Cdc25A was
set at 1. The relative binding of b-TrCP to S76A and
T80A was calculated to be 0.55 ± 0.09 and 0.63 ± 0.09,
respectively. The data is presented as mean ± SEM, n = 3.
(D) U2OS cotransfected with plasmids encoding HA-ubiq-
uitin and the indicated forms of Flag-Cdc25A for 20 hr
were untreated (lanes 1–4, 6–9) or were incubated with
100 nM Go¨6976 for 4 hr (lanes 5, 10) (n = 3). Lysates
were analyzed directly by western blotting (lane 1–5) or ly-
sates were first incubated with Flag agarose and Cdc25A
precipitates were analyzed for ubiquitin by western blot-
ting (lanes 6–10). A representative western blot is shown.
The ratio of ubiquitination to Flag-Cdc25A in each precip-
itate was determined and normalized to wild-type Cdc25A
which was set at 100.T80A mutant was approximately 2.5 times longer than that of
wild-type Cdc25A. Consistent with its longer half-life, the T80A
mutant bound less SCFb-TrCP, a component of SCF E3 ligase
(Figure 5C, lane 5) and was less ubiquitinated than wild-type
Cdc25A (Figure 5D, compare lanes 7 and 9). Given that Chk1
also regulates S76 and Chk1 does not require a priming phos-
phate, it is expected that the properties of T80A mutant, which
should still be a Chk1 substrate, would be less severe than
that of the S76A mutant. The half-life of the S76A mutant was lon-
ger than T80A (Figures 5A and 5B) and it was less ubiquitinated
than the T80A mutant (Figure 5D, compare lanes 8 and 9). Fur-
thermore, Chk1 inhibition decreased T80A ubiquitination to the
level observed for S76A (Figure 5D, compare lanes 8 and 10),
and inhibition of Chk1, but not GSK-3b, extended the half-life
of T80A (Figure S4B). These results demonstrate that although
T80A is insensitive to GSK-3b inhibition in vivo, it retains sen-
sitivity to Chk1 inhibition.
Regulation ofCdc25AbyGSK-3b andChk1as a Function
of the Cell Cycle
To monitor the regulation of Cdc25A by GSK-3b and Chk1
throughout the cell division cycle, synchronized cells were
treated with LiCl to inhibit GSK-3b or with Go¨6976 to inhibit
Chk1, and Cdc25A levels were examined by western blotting
(Figure 6A). DNA content was determined by flow cytometry
(Figure S5A). LiCl-treatment was most effective at stabilizing
Cdc25A during the G1 and S phases of the cell cycle
(Figure 6A, lanes 2 and 5), whereas Go¨6976-treatment was
most effective in the S and G2 phases of the cell cycle (lanes 6and 9). These results suggest that GSK-3b regulates Cdc25A
at early times in the cell division cycle, and Chk1 takes over at
later times. Furthermore, an elevation in BrdU incorporation
was measured when cells synchronized at the G1/S-border
were released from the block in the presence of the GSK-3b
inhibitor LiCl, but not the Chk1 inhibitor Go¨6976 (Figure 6B). To
determine if the enhanced BrdU-incorporation in LiCl-treated
cells was due to Cdc25A stabilization, the experiment was re-
peated in control cells and cells knocked down for Cdc25A (Fig-
ures 6C and 6D). An increase in the number of BrdU-labeled cells
was observed when control cells were treated with LiCl, and this
increase was statistically significant (p = 0.03). In contrast, a sig-
nificant increase in the number of BrdU-positive cells was not
observed when cells knocked down for Cdc25A were treated
with LiCl (p = 0.41). These results suggest that the enhanced
BrdU incorporation observed upon GSK-3b inhibition by LiCl
was due to stabilization of Cdc25A. To determine if the effects
of LiCl were due to GSK-3b inhibition, the experiments were re-
peated in cells knocked down for GSK-3b (Figures S5B and
S5C). Cdc25A accumulated in cells deficient in GSK-3b, and en-
hanced BrdU incorporation was also observed (p = 0.02). LiCl
treatment did not significantly increase Cdc25A or levels of
BrdU incorporation (p = 0.09) in cells knocked down for GSK-
3b (Figures S5B and S5C). A rise in Cdc25A levels and a signifi-
cant increase in BrdU incorporation were also observed when
cells were released from an M phase arrest and then treated
with LiCl (p = 0.03; Figures S5D and S5E). These results suggest
that Cdc25A stabilization by GSK-3b inhibition causes acceler-
ated S phase entry. The relative contribution of APC (Cdh1)Cancer Cell 13, 36–47, January 2008 ª2008 Elsevier Inc. 41
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through siRNA knockdown experiments. As seen in Figure S6,
stabilization of Cdc25A in G1 was observed in cells deficient for ei-
ther Cdh1 or GSK-3b, and even further stabilization was observed
in cells deficient for both proteins. These results demonstrate that
Cdc25A is regulated by APC (Cdh1) and SCF (b-TrCP) in G1.
Correlation between GSK-3b Inactivation and Cdc25A
Overproduction in Multiple Human Tumor Tissues
Cdc25A is overproduced in a wide variety of human cancers and
its overproduction correlates with poor clinical outcome (Krist-
jansdottir and Rudolph, 2004; Loffler et al., 2003). Mechanistic
insight into the cause of Cdc25A overproduction in these can-
cers is lacking. Given that GSK-3b is frequently inactivated in
a variety of tumors (Cohen and Frame, 2001; Doble and Wood-
gett, 2003; Zhou et al., 2004), we tested whether there was a cor-
relation between Cdc25A overproduction and GSK-3b inactiva-
tion using human tumor tissue microarrays derived from different
cancer types (Figure 7 and Table S1). Immunohistochemistry
was performed with a Cdc25A-specific antibody and an anti-
body that recognizes GSK-3b when it is phosphorylated on ser-
ine 9 (p-GSK-3b), a modification that inactivates GSK-3b (Cohen
and Frame, 2001; Doble and Woodgett, 2003). The specificity of
each antibody is shown in Figure S7. As shown in Figure 7, 44 out
of 142 tumor tissues stained positive for p-GSK-3b, demonstrat-
Figure 6. Cell-Cycle Regulation of Cdc25A by
GSK-3b and Chk1
(A) HeLa cells synchronized at the G1/S border using
a double thymidine block and release protocol were re-
leased for 2.5 hr (S phase, lanes 4–6), 6 hr (G2 phase, lanes
7–9), or 11 hr (G1 phase, lanes 1–3). Cells were incubated
with either PBS, 20 mM LiCl, or 100 nM Go¨6976 for 2 hr
prior to harvesting (n = 2). Cells were analyzed by western
blotting in (A) and by flow cytometry (Figure S5A). Relative
levels of Cdc25A were determined from the western blot
using ImageJ program and are indicated above the blot.
(B) HeLa cells were synchronized at the G1/S-border by
a double-thymidine block and release protocol. Synchro-
nized cells were untreated or were incubated with 20 mM
LiCl, or 100 nM Go¨6976 immediately after release from
the block. One hour later, cells were cultured in the pres-
ence of BrdU and harvested 1 hr later. Cells were stained
with PI and for BrdU. The percentage of BrdU-positive
cells was determined by flow cytometry, n = 3.
(C and D) HeLa cells were transfected with control siRNAs
or siRNAs specific for Cdc25A for 24 hr. Cells were syn-
chronized as described in (B), some cells were lysed for
western blotting (C), and the remaining cells were ana-
lyzed as described in (B). (D) A two-tailed t test was per-
formed for comparisons between groups. Standard error
of the mean (SEM) for triplicate samples is shown as error
bars along the y axis. *Statistically significant.
ing that GSK-3b was inactivated in more than
30% of the tumors. Importantly, Cdc25A was
overproduced in 42 out of the 44 tumors con-
taining inactive GSK-3b (p < 0.001 using c2
tests). These findings provide a strong correla-
tion between GSK-3b inactivation and Cdc25A
overproduction in human cancers. Interestingly,
there were 61 tumors that contained high levels of Cdc25A but
stained negative for p-GSK-3b, demonstrating that pathways,
in addition to GSK-3b inactivation, may be involved in Cdc25A
overproduction in human tumors. There was no correlation
between Cdc25A levels with Chk1 or Cdh1 levels in these tumors
(Tables S2 and S3).
DISCUSSION
In this study, we identify GSK-3b as a key kinase that regulates
the ubiquitin-mediated proteolysis of Cdc25A in early phases
of the cell division cycle. We demonstrate that GSK-3b phos-
phorylates Cdc25A on S76 to facilitate the binding of the E3
ubiquitin ligase, SCFb-TrCP. In addition, we demonstrate that
Cdc25A phosphorylation by GSK-3b requires prior phosphoryla-
tion of Cdc25A on T80, and this can be catalyzed by Plk-3.
Importantly, we report a strong correlation between GSK-3b in-
activation and Cdc25A overproduction in several human tumors
of diverse origins suggesting that GSK-3b inactivation may
account for the prevalence of Cdc25A overproduction in many
human cancers.
The periodic fluctuations observed in Cdc25A levels through-
out the cell cycle can be attributed to the action of two distinct
ubiquitin ligase complexes, APCCdh1 and SCFb-TrCP (Busino
et al., 2004; Donzelli et al., 2002; Jin et al., 2003). At mitotic
exit and in G1, Cdc25A ubiquitination and degradation is42 Cancer Cell 13, 36–47, January 2008 ª2008 Elsevier Inc.
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struction in G1 as well as in the S and G2 phases of the cell cycle
(Busino et al., 2004; Busino et al., 2003; Jin et al., 2003). Chk1
phosphorylates Cdc25A during the S and G2 phases of the cell
cycle to regulate its ubiquitin-mediated proteolysis (Hassepass
et al., 2003; Jazayeri et al., 2006; Jin et al., 2003). Consistent
with this, we observed Cdc25A levels rise when S-and G2-,
but not when G1-, phase cells were treated with the Chk1 inhib-
itor Go¨6976. Until now, the identity of the kinase(s) that regulate
recognition of Cdc25A by SCFb-TrCP in late G1 has not been iden-
tified. We observed elevated levels of Cdc25A in G1 cells that
were treated with the GSK-3b inhibitor, LiCl, and we observed
that inhibition of GSK-3b, but not Chk1, accelerated the rate of
S phase entry. These results support the conclusion that
Cdc25A levels are regulated by GSK-3b in G1. Interestingly,
the activity of GSK-3b is the highest in G1 and gradually de-
creases as cells progress toward mitosis (Cohen and Frame,
2001; Doble and Woodgett, 2003).
Elevated levels of Cdc25A were observed when GSK-3b was
inhibited both pharmacologically and with siRNA-treatment. In
addition, GSK-3b bound to and phosphorylated Cdc25A on
a key regulatory site, S76. However, efficient phosphorylation
of Cdc25A by GSK-3b required that Cdc25A first be phosphory-
lated on a priming site, T80. We found that Plk-3 phosphorylated
Cdc25A on T80 and thereby primed Cdc25A for subsequent
phosphorylation by GSK-3b. In addition, ectopic expression of
Plk-3 increased levels of T80-phosphorylated Cdc25A in vivo.
This suggests that Plk-3 functions to negatively regulate
Cdc25A by serving as a priming kinase for GSK-3b, consistent
Figure 7. Inactivation of GSK-3b Correlates with Overexpression of
Cdc25A in Multiple Cancerous Tissues
(A and B) Immunohistochemical staining of p-GSK-3b (Ser9) and Cdc25A were
performed using multiple cancerous tissue microarrays. Representative
examples of p-GSK-3b and Cdc25A staining in the same tumor are shown in
(B), and a summary of the results is shown in (A). The scale bar is 50 mm.with the literature showing that Plk-3 is active in the G1 phase
of the cell cycle when GSK-3b is expected to regulate Cdc25A
(Myer et al., 2005). Given that S76 phosphorylation is a prerequi-
site for subsequent phosphorylation of S82, which is critical for
b-TrCP binding, and that Chk1 also phosphorylates S76 (Bartek
and Lukas, 2003; Busino et al., 2003; Donzelli et al., 2004; Golou-
dina et al., 2003; Hassepass et al., 2003; Jin et al., 2003; Ray
et al., 2005; Sorensen et al., 2003), we propose that the coordi-
nated activities of GSK-3b and Chk1 tightly regulate Cdc25A
levels throughout the cell cycle (Figure 8). The PI-3K/AKT path-
way negatively regulates both GSK-3b and Chk1 and this, in
turn, promotes cell-cycle advancement by elevating Cdc25A
levels (Cohen and Frame, 2001; Puc et al., 2005; Shtivelman
et al., 2002). Recently, Ray et al. (2005) reported that transform-
ing growth factor b (TGF-b) signaling induces ubiquitin-mediated
proteolysis of Cdc25A through SCFb-TrCP-mediated binding, and
this occurs in a Chk1-independent manner. It will be interesting
to determine if GSK-3b plays a role in the destruction of
Cdc25A by TGF-b.
Cdc25A is rapidly targeted for ubiquitin-mediated proteolysis
in cells exposed to genotoxic stress (Falck et al., 2001, 2002;
Mailand et al., 2000; Zhao et al., 2002), and Chk1 plays a key
role in regulating Cdc25A levels following exposure of cells to
replicative stress and to DNA damage (Zhao et al., 2002). Here,
we demonstrate that the ability of cells to efficiently degrade
Cdc25A in response to genotoxic stress also requires GSK-3b
activity and that GSK-3b cooperates with Chk1 to target
Cdc25A for degradation in response to IR. Although it is known
that Chk1 acts downstream of ATR in the replicative stress path-
way and downstream of ATM/ATR in the DNA double-strand
break pathway (Jazayeri et al., 2006; Liu et al., 2000; Zhao and
Piwnica-Worms, 2001), it is not known how GSK-3b activity is
regulated by various forms of genotoxic stress.
Cdc25A is able to transform primary mouse embryo fibroblasts
in cooperation with activated Ras or loss of RB, and Cdc25A is
frequently overproduced in human cancers both at the RNA
and protein levels (Broggini et al., 2000; Cangi et al., 2000; Galak-
tionov et al., 1995; Gasparotto et al., 1997; Kristjansdottir and
Figure 8. Model of Cdc25A Regulation
A proposed model to illustrate how the GSK-3b pathway coordinates with the
Chk1 pathway to modulate Cdc25A levels during an unperturbed cell cycle, in
response to DNA damage, and in certain cancer cells.Cancer Cell 13, 36–47, January 2008 ª2008 Elsevier Inc. 43
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pathways leading to Cdc25A accumulation in human cancers
have not been identified. Importantly, GSK-3b inactivation is
a common occurrence in human cancers, and we observed
a strong correlation between GSK-3b inactivation and Cdc25A
overproduction in several human tumors of diverse origins.
Thus, inactivation of GSK-3b signaling pathways correlates
with Cdc25A overproduction in a subset of human cancers.
GSK-3b is present in the nucleus and the cytoplasm of cells,
and its activity is modulated by several signaling and develop-
ment pathways, including the Wnt, PI-3K/AKT, and Ras/MAPK
pathways (Cohen and Frame, 2001; Ding et al., 2005; Doble and
Woodgett, 2003; Zhou et al., 2004). GSK-3b inactivation is a com-
mon occurrence in human cancers and this is due, in part, to the
tendency of cancer cells to constitutively activate the PI-3K/AKT
and Ras/MAPK pathways. Indeed, 44 out of 142 cancer tissues
examined contained inactive GSK-3b. Importantly, 42 out of the
44 tissues containing inactive GSK-3b also contained high levels
of Cdc25A, supporting the conclusion that derailment of GSK-3b
signaling correlates with the overproduction of Cdc25A in a sub-
set of human cancers. Cdc25A overproduction may contribute to
the genomic instability observed in these cancers. We also found
61 tumors that contained active GSK-3b and high levels of
Cdc25A, demonstrating that pathways, in addition to GSK-3b
inactivation, may be involved in Cdc25A overproduction. We
demonstrated that Plk-3 can phosphorylate and thereby prime
Cdc25A for subsequent phosphorylation by GSK-3b and that
Cdc25A accumulates in cells knocked down for Plk-3. This sug-
gests that Plk-3 may function to negatively regulate Cdc25A by
serving as a priming kinase for GSK-3b. Interestingly, Plk-3 has
been shown to be inactivated in multiple tumor samples (Takai
et al., 2005). Tumors that inactivate Plk-3 are predicted to
overproduce Cdc25A by reducing phosphorylation of S76 by
GSK-3b. Thus, Plk-3 inactivation may account for Cdc25A over-
production in a subset of human tumors as well.
A therapeutic strategy that is currently being developed to treat
p53-deficient cancers is to combine DNA damaging agents with
drugs, such as UCN-01, that cause Cdc25A levels to rise. This in-
duces preferential killing of p53-deficient tumor cells because it
eliminates all DNA damage checkpoints in p53-deficient tumors.
Phase I and II clinical trials combining UCN-01 with DNA damaging
agents are currently underway to treat various cancer types
(Bunch and Eastman, 1996; Busby et al., 2000; Dees et al., 2005;
Fuse et al., 1998; Graves et al., 2000; Hotte et al., 2006; Kohn
et al., 2003; Kortmansky et al., 2005; Levesque et al., 2005; Perez
et al., 2006; Sampath etal., 2006; Sausville etal., 2001; Wanget al.,
1996; Yu etal., 1998).Our study identifies GSK-3band Plk-3 aspo-
tential therapeutic targets whose inhibition may induce checkpoint
bypass in tumors by blocking Cdc25A proteolysis. Furthermore,
tumors from patients enrolled on clinical trials that depend on
Cdc25A stabilization to induce checkpoint bypass should be
tested for the integrity of the GSK-3b/Plk-3/Cdc25A pathway in
order to correlate Cdc25A levels with tumor responses.
EXPERIMENTAL PROCEDURES
Cell Lines
Cells (HeLa, U2OS, MCF-7, HEK293, Saos2, BT549, MDA-MB-231, A549,
H460, and IMR90) were cultured according to the instructions from ATCC,44 Cancer Cell 13, 36–47, January 2008 ª2008 Elsevier Inc.and immortalized MEFs (wild-type or null for GSK-3b) were grown in Dulbec-
co’s modified Eagle’s medium (DMEM, Invitrogen) supplemented with 10%
bovine growth serum (BGS, Hyclone), 1 mM glutamine, and 100 U/ml each
of penicillin and streptomycin.
Plasmids
Plasmids encoding human Cdc25A have been described (Chen et al., 2003).
V5-tagged Wild-type (WT), constitutively active (CA), and kinase-inactive
(KD) GSK-3b were obtained using the Gateway System (Invitrogen) with
myc-tagged plasmids as templates. Plasmids encoding HA-GSK-3b-CA
(Wei et al., 2005), Myc-GSK-3b, Myc-b-TrCP, and HA-Ubiquitin (Zhou et al.,
2004) have been described. Mutations were introduced using the QuikChange
site directed mutagenesis kit (Stratagene), and all mutations were verified by
DNA sequencing.
Antibodies
Human Cdc25A was detected with mouse monoclonal antibody Ab-3 (Neo-
markers). Antibodies specific for Cdc25A phosphorylated on S76 have been
described (Goloudina et al., 2003). GSK-3b antibodies and antibodies specific
for GSK-3b phosphorylated on serine 9 (p-Ser9) were purchased from Cell Sig-
naling Technology. Other primary antibodies used for western blotting were
anti-Flag (Sigma Chemical Co.), anti-V5 (Invitrogen), anti-b-catenin (BD Trans-
duction), anti-actin (Sigma Chemical Co.), anti-GSK-3a (Santa Cruz), which
also reacts with GSK-3b, anti-Chk1 (Santa Cruz), anti-Myc (A-14, Santa
Cruz) for tagged protein, anti-Myc (N-262, Santa Cruz) for endogenous Myc,
anti-HA (Santa Cruz), anti-Plk-2 (Santa Cruz), and anti-Plk-3 (BL1697, BETHYL
Laboratories, Inc.). Antibodies specific for Cdc25A phosphorylated on T80 and
S123 were generated by immunizing rabbits with the coupled phosphopepti-
des C-GSSES-pT-DSGFC and C-LKRSH-pS-DSLD, respectively. Bound
primary antibodies were detected with either horseradish peroxidase (HRP)-
conjugated goat anti-mouse antibody (Jackson) or HRP-goat anti-rabbit anti-
body (Zymed), and proteins were visualized by chemiluminescence.
Transfection Experiments
Asynchronously growing cells seeded at 2.5 3 105 cells per well of a 6-well
tissue culture dish or at 1 3 106 cells per 100 mm tissue culture dish were
transfected with 2 mg or 10 mg plasmid DNA, respectively, using Lipofectamie
2000 (Invitrogen).
Treatment of Cells with Chemical Inhibitors
Asynchronously growing cells were incubated in media containing either 100
nM Go¨6976, 10 mM LiCl, 10 mM MG132, or a combination of LiCl and
MG132 or Go¨6976 at the indicated concentrations for 4 hr. To obtain mitotic
cells, cells were incubated with 50 ng/ml of nocodazole for 16–18 hr. Cells
were lysed in mammalian cell lysis buffer (MCLB: 50 mM Tris-HCl pH 8.0,
2 mM DTT, 5 mM EDTA, 0.5% Nonidet P-40, 100 mM NaCl, 1 mM microcystin,
1 mM sodium orthovanadate, 2 mM PMSF, protease [Sigma Chemical Co.],
and phosphatase inhibitor cocktail [Calbiochem]). LiCl was purchased from
Sigma Chemical Co. and MG132 and Go¨6976 were purchased from Calbio-
chem.
RNAi Treatment
Knockdown of GSK-3b, Chk1, Cdc25A, Cdh1, Plk-1, Plk-2, Plk-3, and Plk-4
was accomplished using Smartpool siRNA (Dharmacon). Approximately 2 3
105 HeLa cells were seeded per well of a 6-well tissue culture dish the day be-
fore transfection. Transfection was performed according to the manufacturer’s
instructions using Dharmafect 3 transfection reagent (Dharmacon) and 100 nM
siRNA. Forty-eight hours posttransfection, cells were incubated in the pres-
ence or absence of 20 mg/ml cycloheximide for the indicated times and
harvested in MCLB. Alternatively, cells were exposed to 10 Gy IR and har-
vested in MCLB. Smartpool siRNA reagents (Dharmacon) were scrambled
control (D00121002), luciferase GL3 (D00140001), GSK-3b (M00301003),
Chk1 (M00892700), Cdc25A (Zhao et al., 2002), Cdh1 (M01537701), Plk-3
(L00325700), Plk1 (L00329000), Plk2 (L00332500), and Plk4 (L00503600).
Western Blotting and Immunoprecipitations
Cells were lysed in MCLB. Clarified lysates were resolved by SDS-PAGE and
transferred to nitrocellulose membranes for western blotting using either ECL
Cancer Cell
GSK-3b/Cdc25A Regulatory Pathwaydetection reagents (Amersham Biosciences), Millipore Immobilon detection
reagents (Millipore Co.), or SuperSignal reagents (Pierce). Alternatively, clari-
fied supernatants were first incubated with anti-Flag- or anti-V5-agarose
(Sigma Chemical Co.) for 1 to 2 hr at 4C, and precipitates were washed
four times with MCLB. In the case of endogenous Cdc25A, rabbit anti-
Cdc25A (sc-97, Santa Cruz) and protein A plus G beads (Santa Cruz) were
used. In some cases, proteins were visualized and quantified using the ECL
plus reagent (Amersham), which contains a chemifluorescence component
for quantification on a Molecular Dynamics Storm Imager (Molecular Biosys-
tems, Piscataway, NJ).
Kinase Assays
GST-Cdc25A was produced in bacteria and purified as described previously
(Chen et al., 2003). GST-Cdc25A was eluted from GSH agarose in buffer con-
sisting of 50 mM Tris (pH 7.4), 20 mM glutathione, 2 mM PMSF, 10 mg/ml of
aprotinin, and 20 mM leupeptin at 4C. Plk-3 was purified from Sf9 cells in-
fected with recombinant baculovirus encoding His6-tagged-Plk-3. Active
GST-GSK-3b was purchased from Cell Signaling. Kinase reactions were car-
ried out in a reaction buffer consisting of 50 mM Tris-HCl, pH 7.4, 1 mM DTT,
10 mM MgCl2, 500 mM ATP, 2 mg of soluble GST-Cdc25A, 100 ng of either
GSK-3b or Plk3, or a combination of 100 ng each of GSK-3b and Plk-3. Reac-
tions were incubated at 30C for 1 to 2 hr and then resolved by SDS-PAGE fol-
lowed by western blotting.
Synchronization of HeLa Cells
HeLa cells, synchronized at the G1/S-border using a double thymidine block
and release protocol (Chen et al., 2003), were released into culture media for
2.5 hr (S phase cells), 6 hr (G2 phase cells) or 11 hr (G1 phase cells). Synchro-
nized cells were either not treated or were incubated with 20 mM LiCl or
100 nM Go¨6976 for 2 hr prior to collection for analyzing by flow cytometry and
western blotting. Alternatively, HeLa cells were cultured in the presence of
50 ng/ml nocodazole for 18 hr and mitotic cells were isolated by mitotic shake
off. Cells were washed twice with PBS and cultured for 8 hr (G1 phase cells),
12 hr (S phase) or 15 hr (G2 phase). Synchronized cells were either not treated
or were treated with 20 mM LiCl or 100 nM Go¨6976 for 2 hr. Cell were collected
and analyzed by flow cytometry and western blotting.
Flow Cytometry
Cells were harvested by trypsinization and collected by centrifugation. Cells
were washed once with PBS and fixed in 5 ml of 70% ethanol at 4C. Cells
were washed once with PBS/1% BSA and then incubated with 1 ml of PBS/
1% BSA containing 30 mg/ml propidium iodide (PI) and 0.25 mg/ml RNase A
for 1 hr at room temperature. Cells were analyzed for DNA content by flow
cytometry using a FACS Calibur (BD Biosciences). The data were analyzed
using CellQuest Analysis software (BD Biosciences).
BrdU Labeling
HeLa cells, synchronized in mitosis with nocodazole, were washed twice with
PBS and cultured for 9 hr. Alternatively, HeLa cells were synchronized at the
G1/S-border using a double thymidine block and release protocol (Chen
et al., 2003). Cells were treated with vehicle (PBS), 20 mM LiCl, or 100 nM
Go¨6976 for 1 hr. Cells were then incubated with 20 mM bromodeoxyuridine
(BrdU) for 1 hr and then processed for flow cytometry as described (Ferguson
et al., 2005). In some cases, HeLa cells were first transfected with siRNAs for
24 hr. Statistical analysis was performed using a two-tailed t test.
Analysis of Human Tumor Tissue
Human tumor tissue microarrays were purchased from IMGENEX (cat no.
IMH-365). This tissue microarray is a high density slide (146 samples in which
142 were available for analysis in this study) containing multiple cancerous tis-
sues. Rabbit polyclonal anti-human Cdc25A antibody (SC-97, Santa Cruz) was
used at 1:500. Rabbit polyclonal anti-human phospho-GSK3b (Ser9) (no. 9336,
Cell Signaling Technology) was used at 1:30. Rabbit polyclonal anti-human
Cdh1 antibody (Zymed, no. 34-2000) was used at 1:20 and monoclonal anti-
human Chk1 antibody (Sigma, no. C9358) was used at 1:3,000. Tissue slides
were deparaffinized in xylene and rehydrated in a series of graded alcohols,
and the antigen was retrieved in 0.01 M sodium citrate buffer (pH 6.0) using
a microwave oven. The sections were then treated with 1% hydrogen peroxidein methanol for 30 min to exhaust endogenous peroxidase activity. After a 1 hr
preincubation in 10% normal goat serum to prevent nonspecific staining, the
samples were incubated with primary antibody at 4C overnight. The sections
were then treated with biotinylated goat anti-rabbit immunoglobulin followed
by incubation with avidin-biotin peroxidase complex solution for 1 hr at
room temperature. The peroxidase reaction was visualized by incubating the
sections with 3-amino-9-ethylcarbazole solution. The counterstaining was
carried out using Mayer’s hematoxylin. Cdc25A expression was classified as
positive in cases with more than 50% positive-staining cells with other cases
classified as negative. In the case of GSK-3b, Chk1, and Cdh1, cases with
more than 10% positive-stained cells were classified as positive and others
as negative. Statistical analysis was done using SPSS, version 10. Association
between the phospho-GSK-3b, Chk1, and Cdh1 with Cdc25A abundance was
assessed using c2 tests. The Institutional Review Board of the University of
Texas M.D. Anderson Cancer Center has determined that the use of the human
tumor tissue microarray is exempt under Category Number 4.
Peptide Competition
Peptides were mixed with primary antibodies prior to incubating with the se-
quential breast cancer tissue sections. Peptides included Cdc25A blocking
peptide (SC-97P, Santa Cruz) diluted 1:125, phospho-GSK3b (Ser 9) blocking
peptide (no. 900, Cell Signaling Technology) diluted 1:7.5. Control peptides
were unrelated to the antibodies used and were diluted as indicated above.
Supplemental Data
The Supplemental Data include seven supplemental figures and three supple-
mental tables and can be found with this article online at http://www.
cancercell.org/cgi/content/full/13/1/36/DC1/.
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